In vivo effects of romidepsin on T-cell activation, apoptosis and function in the BCN02 HIV-1 kick&kill clinical trial

Romidepsin (RMD) is a well-characterized histone deacetylase inhibitor approved for the treatment of cutaneous T-cell lymphoma. in vitro and in vivo studies have demonstrated that it is able to induce HIV-1 gene expression in latently infected CD4+ T cells from HIV-1+ individuals on suppressive anti...

Mô tả đầy đủ

Chi tiết về thư mục
Những tác giả chính: Rosás-Umbert, M, Ruiz-Riol, M, Fernández, MA, Marszalek, M, Coll, P, Manzardo, C, Cedeño, S, Miró, JM, Clotet, B, Hanke, T, Moltó, J, Mothe, B, Brander, C, BCN02 study group
Định dạng: Journal article
Ngôn ngữ:English
Được phát hành: Frontiers Media 2020

Những quyển sách tương tự